Experts Addressed Clinical Trial Racial Disparities
A panel identified a persistent lack of Black patient recruitment as a primary barrier to medical research participation.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you trust that medical research in your area adequately serves all patient populations?
Experts gathered to discuss the underrepresentation of Black patients in clinical trials, where participation levels fail to reflect the broader U.S. population. While Black Americans make up 14% of the population, they account for only 8% of research participants.
Why it matters
Clinical research requires complete data across diverse demographics because diseases impact patients differently based on race, age, and weight. Currently, systemic barriers prevent many from accessing trials, limiting the understanding of how new medicines perform.
Communities of color comprise over 40% of the U.S. population but represent only 1 out of 4 clinical trial participants. In 2023, Black patient participation in lung cancer trials reached 4.4%, trailing the 7.2% participation rate for white patients.
The players
Congressional Black Caucus Foundation
This organization hosts the annual legislative conference where experts discussed medical research disparities.
National Academies
This institution publishes research and reports on public policy, including a 2022 analysis of minority participation in trials.
Merck
This pharmaceutical company initiated a grassroots program in 2018 intended to increase diversity in clinical research.
The details
Panelists analyzed long-standing systemic barriers to research and noted that advocates are now distributing educational brochures and videos to help patients discuss trials with providers. Despite industry efforts such as a 2018 grassroots initiative, progress remains slow in matching participant demographics to disease prevalence.
Timeline
Merck launched a grassroots effort to improve representation in 2018.
The National Academies published a report on trial participation trends in 2022.
Data showed Black lung cancer trial participation was 4.4% in 2023.
The panel discussion took place on September 25, 2026.
The Big Picture
This discussion updates the findings from the National Academies' 2022 report on minority participation, which highlighted three decades of limited progress in diversifying research cohorts. The current data illustrates a pattern of ongoing disparities that complicate the broader development of medical treatments.
Patients may benefit from new educational resources, including brochures and videos, designed to help them discuss trial opportunities with their healthcare providers. Increased diversity in research will eventually lead to treatments that are better tailored to the specific needs of diverse populations.
The takeaway
Achieving health equity in research requires both systemic reform and proactive patient education to overcome historic barriers. Patients should consult with their providers about trial availability as part of their standard care strategy.
Further reading
For more context on medical research trends, visit the Cancer section.
More information
To search for active research, visit the federal registry of clinical studies.
Source note: This article includes information reported by The Seattle Medium.
Live Poll
Do you trust that medical research in your area adequately serves all patient populations?
